

1 **Title page**

2

3 **Full-length title:**

4 **The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the**
5 **fate of RNA virus epidemics and obeys the Black Queen rule**

6

7 **Short title (for the running head):**

8 **SARS-CoV-2 variant spread and vanishing**

9

10 **Author list: Philippe COLSON^{1,2,3}, Philippe GAUTRET^{1,2,4}, Jeremy DELERCE¹, Hervé**
11 **CHAUDET^{1,4,5}, Pierre PONTAROTTI^{1,6}, Patrick FORTERRE^{7,8}, Raphael TOLA^{1,2},**
12 **Marielle BEDOTTO¹, Léa DELORME^{1,4,5}, Anthony LEVASSEUR^{1,3}, Jean-Christophe**
13 **LAGIER^{1,2,3}, Matthieu MILLION^{1,2,3}, Nouara YAHI⁹, Jacques FANTINI⁹, Bernard LA**
14 **SCOLA^{1,2,3}, Pierre-Edouard FOURNIER^{1,2,3}, Didier RAOULT^{1,3} ***

15 **Affiliations:** ¹ IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,
16 France; ² Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005
17 Marseille, France; ³ Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD),
18 Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and
19 Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille, France; ⁴ Aix-Marseille
20 Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux
21 de Marseille (AP-HM), Vecteurs - Infections Tropicales et Méditerranéennes (VITROME),
22 27 boulevard Jean Moulin, 13005 Marseille, France; ⁵ French Armed Forces Center for
23 Epidemiology and Public Health (CESPA), Camp de Sainte Marthe, BP 40026 Marseille
24 Cedex 02; ⁶ Centre national de la recherche scientifique (CNRS), Marseille, France; ⁷ Institut
25 Pasteur, Département de Microbiologie, 25 rue du Docteur Roux, 75017, Paris, France; ⁸

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC),
27 91198, Gif-sur-Yvette, France; ⁹ INSERM UMR_S 1072, Boulevard Pierre Dramard, Aix-
28 Marseille Université, 13015 Marseille, France.

29 * **Corresponding author:** Didier Raoult, IHU - Méditerranée Infection, 19-21 boulevard Jean
30 Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:
31 didier.raoult@gmail.com

32

33 **Keywords:** SARS-CoV-2; variants; epidemic; Marseille-4; Pangolin B.1.1.160; ORF8

34 **Word counts:** abstract, 190; text, 1,674

35 **Figures:** 3; **Table:** 1; **References:** 31

36 **Supplementary Material: Tables:** 3; **Figures:** 3

37 **Summary**

38

39 **The nature and dynamics of mutations associated with the emergence, spread and**
40 **vanishing of SARS-CoV-2 variants causing successive waves are complex¹⁻⁵. We**
41 **determined the kinetics of the most common French variant (“Marseille-4”) for 10**
42 **months since its onset in July 2020⁵. Here, we analysed and classified into subvariants**
43 **and lineages 7,453 genomes obtained by next-generation sequencing. We identified two**
44 **subvariants, Marseille-4A, which contains 22 different lineages of at least 50 genomes,**
45 **and Marseille-4B. Their average lifetime was 4.1 ± 1.4 months, during which 4.1 ± 2.6**
46 **mutations accumulated. Growth rate was 0.079 ± 0.045 , varying from 0.010 to 0.173. All**
47 **the lineages exhibited a “gamma” distribution. Several beneficial mutations at**
48 **unpredicted sites initiated a new outbreak, while the accumulation of other mutations**
49 **resulted in more viral heterogeneity, increased diversity and vanishing of the lineages.**
50 **Marseille-4B emerged when the other Marseille-4 lineages vanished. Its ORF8 gene was**
51 **knocked out by a stop codon, as reported in several mink lineages and in the alpha**
52 **variant. This subvariant was associated with increased hospitalization and death rates,**
53 **suggesting that ORF8 is a nonvirulence gene. We speculate that the observed**
54 **heterogeneity of a lineage may predict the end of the outbreak.**

55

56 **Text**

57

58 **Introduction**

59 The shape of epidemic curves of acute infectious diseases is the subject of several hypotheses
60 and interpretations. The occurrence of successive waves of SARS-CoV-2 infections during
61 the current pandemic was linked to the emergence of viral variants¹⁻⁵, while possible causes of

62 the extinction of epidemics are viral load decrease⁶, herd immunity⁷ (as hypothesized for
63 influenza viruses)⁸, or the implementation of treatment or vaccination⁹. However, the factors
64 and mechanisms involved in the rise and fall of SARS-CoV-2 variants have not been
65 elucidated. We identified in July 2020 at IHU Méditerranée Infection, Marseille, France
66 (which generated 20% of the genomes deposited in GISAID (<https://www.gisaid.org/>)¹⁰ by
67 France as on 16/12/2021), a new SARS-CoV-2 variant, named Marseille-4 (later classified as
68 lineage 20A.EU2 and B.1.160 in Nextstrain and Pangolin classifications)¹¹. This variant is
69 characterized by 20 mutations, including 13 specific compared with the Wuhan-Hu-1
70 isolate^{5,11}. Seven mutations are nonsynonymous, including one in the spike glycoprotein
71 (S477N). We analysed the epidemiological source and features of this variant and
72 accumulated genetic data through extensive SARS-CoV-2 genomic surveillance by next-
73 generation sequencing from its onset until its disappearance 10 months later in April of 2021.
74 Thus, we could study the nature and dynamics of mutations associated with its emergence,
75 spread, and vanishing.

76

77 **Results**

78

79 **Kinetics of the Marseille-4 variant infection**

80 The identification of the Marseille-4 variant in late July 2020¹¹ (Figure 1a) led to design a
81 specific qPCR to evaluate its incidence and 9,616 cases were identified. It was the third most
82 commonly diagnosed variant at our institution after variants Alpha/B.1.160 (n= 10,139) and
83 Delta/B.1.617.2 (11,060). By contrast, it was rarely observed during this period in the UK or
84 Spain, where the Marseille-2/B.1.177 variant predominated (Figure 1b). The shape of the
85 incidence curve of Marseille-4 differed from that of mutants of the Wuhan-Hu-1 isolate or of
86 alpha and delta variants that show a “gamma” distribution¹². The curve of Marseille-4
87 included several peaks, with a first in September (week 37), a second in October (week 43),

88 and a third in January 2021 (week 2) before the variant vanished in April 2021 (Figure 1a).

89 **Marseille-4 subvariants and lineages**

90 Next-generation sequencing was performed when cycle threshold values (Ct) of qPCR was
91 <30 and a genome was obtained from 7,453 patients (Figure 1a). Phylogenetic analysis and
92 comparative genomics identified two subvariants, i.e. new variants issued from a circulating
93 variant (Marseille-4A and Marseille-4B). The Marseille-4A subvariant contained 22 different
94 lineages of at least 50 SARS-CoV-2 genomes harbouring one to four hallmark nucleotide
95 changes (Figure 2a; Supplementary Tables S1, S2, S3). Interestingly, the single sequence
96 reported from an infected mink farm in France was a Marseille-4A variant¹¹. The growth rate
97 varied throughout the Marseille-4 epidemic for each subvariant and lineage (Figures 2b-g;
98 Supplementary Figure S1; Supplementary Tables S2, S3). It was 0.079 ± 0.045 on average and
99 varied from 0.010 for the Marseille-4A.17 lineage to 0.173 for the Marseille-4A.15 lineage.
100 Thus, we observed heterogeneous growth rates for Marseille-4 subvariants and lineages, as
101 indicated by a very high ratio of true heterogeneity to the total observed variation ($I^2 = 99\%$; p
102 < 0.05 ; Supplementary Figure S2).

103 **ORF8 gene inactivation in the Marseille-4B subvariant**

104 The Marseille-4B subvariant spread from September 2020 to March 2021 with a gamma
105 distribution of cases (Figure 1a; Supplementary Tables S2, S3). It expanded significantly in
106 December 2020 during the vanishing of the other lineages. It exhibited a mean number of
107 4.1 ± 1.6 lineage-specific mutations (range, 0-15; $n = 1,319$ genomes). Interestingly, the ORF8
108 gene was knocked out at the origin of the Marseille-4B variant. This gene may play a key role
109 in immune modulation and increases virus multiplication¹³. Its inactivation by a stop codon
110 has been reported in several mink lineages and in all genomes of the Alpha variant.
111 The dimeric structure of the ORF8 protein (wild-type and mutant forms) is shown in Figure
112 3a-c. The dimer is stabilized by a covalent bond (a disulfide bridge) between two cysteine

113 residues in the N-terminal region of each subunit¹⁴. Mutation A65S does not induce major
114 structural or electrostatic surface potential alterations (Figure 3b). Both the initial A65 and
115 mutant A65S residues are well exposed to the solvent and occupy approximately the same
116 volume. By contrast, the truncated 18-63 form leads to a different protein, despite its sequence
117 identity with the 18-63 region of the initial ORF8 protein chains (Figure 3c). The electrostatic
118 surface potential of the truncated protein is also significantly affected, with an increase in both
119 neutral and electronegative surface areas. These structural data suggest a total loss of ORF8
120 function for the truncated 18-63 form. Finally, mutation H17Y affects the C-terminal residue
121 of the signal peptide, so it is not present in the mature form of ORF8, as shown in Figure 3a-c.

122 **Severity of the Marseille-4B subvariant infections**

123 We compared the characteristics of the first 181 patients identified as infected with Marseille-
124 4B and 1,647 patients identified as infected with Marseille-4A (Table 1a-b). Patients infected
125 with Marseille-4B were more likely to be female and older than those infected with Marseille-
126 4A. The mean Ct values did not differ between the two groups of patients. Higher
127 hospitalization and death rates were observed in patients infected with Marseille-4B.
128 Multivariate analysis (Table 1b) confirmed that increased hospitalization rate was
129 significantly associated with male sex, older age, a lower viral load (increased Ct value) and
130 Marseille-4B infection. An increased rate of transfer to the intensive care unit was
131 significantly associated with male sex and older age. An increased death rate was significantly
132 associated with male sex, older age and Marseille-4B infection. Thus, we concluded that
133 Marseille-4B was more virulent and suspected that it is related to the knock-out of ORF8.

134 **Some mutations are associated with expansion of Marseille-4A lineages, other with their** 135 **vanishing**

136 Analysing the kinetics of new variants without enough viral sequences leads to confused
137 interpretation because of the superposition of different lineages in this clade. As for Marseille-

138 4, we identified nucleotide changes among the 22 Marseille-4A lineages. Most of the
139 Marseille-4 subvariants and lineages showed a gamma distribution of cases with a lifetime of
140 4.1 ± 1.4 months on average (Supplementary Figure S3), during which 4.1 ± 2.6 mutations
141 accumulated in viral genomes. RNA viruses have a high mutation rate^{15,16} and SARS-CoV-2
142 accumulates approximately one mutation every 2 weeks¹⁷. We found signature mutations in
143 each of these lineages, including in the Nsp1, Nsp2, NSp2, spike, ORF7a, ORF7b, and ORF8
144 genes (Supplementary Table S1; Figure 3d). Interestingly, the accumulation of mutations
145 resulting in an increasing genetic divergence correlated with a decreased incidence. Thus, the
146 accumulation of nonlethal and nonfavouring mutations leads gradually to a dispersion of the
147 lineages, a decrease in viral fitness and vanishing of the epidemic.

148

149 **DISCUSSION**

150 Here, we described the complete cycle of emergence, spread and vanishing of the Marseille-4
151 variant identified in France from mink¹¹ by analysing 7,453 genomes. The viral mutation rate
152 leads to the accumulation of many random mutations, most presumably mildly deleterious,
153 with little effect on fitness. Only 10^{-8} may be associated with a fitness gain^{15,18,19}. Overall, the
154 RNA virus fitness evolution includes an initial period of rapid multiplication possibly caused
155 by a positive mutation followed by the decline of viral fitness caused by accumulation of unfit
156 mutations, as described for the vesicular stomatitis virus^{15,20}.

157 We observed heterogeneity of the growth rates for the different Marseille-4 subvariants and
158 lineages, making it challenging to generalize the behaviour of one SARS-CoV-2 subvariant or
159 lineage to all of them. All Marseille-4 lineages present a genetic signature with mutations
160 sometimes associated with the inactivation of ORF7a or ORF7b, as described²¹. None of these
161 mutations, apart from those located in the spike gene, were predicted to be possibly associated
162 with increased transmissibility. Knock-out of the ORF8 and ORF7a/b genes shows that

163 SARS-CoV-2 virulence may be associated with a loss of genes, as shown for bacteria in
164 which the decline in genomic content is often associated with an increased specificity and
165 virulence²². Analysis of the Marseille-4B subvariant revealed the presence of a stop codon in
166 ORF8, which was observed in the alpha variant and viruses infecting minks and pangolins²³.
167 Marseille-4B subvariant is more virulent, at a time when the other Marseille-4 lines had
168 vanished or were vanishing. This finding suggests that this gene may be a so-called
169 “nonvirulence gene”²⁴ and that SARS-CoV-2 may follow the “Black Queen” hypothesis,
170 which proposes that the loss of a gene may provide a selective advantage when its function is
171 dispensable²⁵, leading to the uselessness of correcting inactivating mutations on the “Use it or
172 lose it” model²⁶. As expected, structural analysis of the truncated form of ORF8 (ORF8 18-
173 63) confirms that the large deletion induced by the stop codon results in a distinct protein that
174 does not retain any resemblance to the native ORF8 dimer. Interestingly, partial or complete
175 deletions of the ORF8 gene were observed during the middle and late phases of the SARS-
176 CoV epidemic in 2002-2003²⁷. Additionally, the knock-out of these genes suggests that
177 SARS-CoV-2 originates from a distinct animal reservoir, explaining why several of its genes
178 are not essential and may be knocked-out in humans, minks and pangolins. Similarly, ORF8
179 truncation has been hypothesized to have occurred for HCoV-229E in humans after zoonotic
180 transmission from bats or intermediate hosts²⁸. Functionally, ORF8 may help the virus to
181 adapt to new hosts by facilitating immune evasion due to functional mimicry with
182 immunological molecules²⁹. This function may not remain critical as soon as the virus is well
183 adapted to its new hosts. Interestingly, evolutionary changes in virulence observed for
184 myxoma virus after its introduction as a biological control in rabbits of Australia were often
185 associated with losses of gene functions³⁰.
186 Regarding the spread of these Marseille-4 lineages, their average detection duration was
187 approximately 4 months, indicating that the accumulation of mutations beyond 8 was

188 associated with a vanishing. This accumulation of mutations is associated with genetic
189 heterogeneity and increased diversity. This leads to a funnel-shaped evolution of the viral
190 population. Overall, several beneficial mutations at unpredicted sites increase fitness, while
191 the accumulation of other mutations results in decreased fitness, loss of clonality and
192 vanishing of the lineage. We speculate that the observed heterogeneity of a lineage may
193 predict the end of the outbreak.

194

195

196 **References**

197

- 198 1. Lemey, P. et al. Untangling introductions and persistence in COVID-19 resurgence in
199 Europe, *Nature*. **595**, 713 (2021).
- 200 2. Li, J., Lai, S., Gao, G.F., & Shi, W. The emergence, genomic diversity and global spread
201 of SARS-CoV-2. *Nature*. **600**, 408-418 (2021).
- 202 3. Vöhringer, H.S. et al. Genomic reconstruction of the SARS-CoV-2 epidemic in England.
203 *Nature*. **600**, 506-511 (2021).
- 204 4. Rochman, N. D. et al. Ongoing global and regional adaptive evolution of SARS-CoV-2,
205 *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2104241118 (2021).
- 206 5. Colson, P. et al. Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the
207 role of globalisation and zoonosis in pandemics, *Front. Microbiol.*, Online ahead of print
208 (2022).
- 209 6. Hay, J. A. et al. Estimating epidemiologic dynamics from cross-sectional viral load
210 distributions, *Science* **373** (2021).
- 211 7. Omer, S. B., Yildirim, I. & Forman, H. P. Herd Immunity and Implications for SARS-
212 CoV-2 Control, *JAMA* **324**, 2095 (2020).

- 213 8. Palese, P. & Wang, T. T. Why do influenza virus subtypes die out? A hypothesis, *MBio*.
214 2 (2011).
- 215 9. Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-
216 CoV-2 variants, *Science* **373**, 1372 (2021).
- 217 10. Elbe, S., & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
218 contribution to global health. *Glob Chall* **1**, 33-46 (2017).
- 219 11. Fournier, P. E. et al. Emergence and outcomes of the SARS-CoV-2 'Marseille-4' variant,
220 *Int. J. Infect. Dis.* **106**, 228 (2021).
- 221 12. Moran, P. A. P. Statistical inference with bivariate gamma distributions, *Biometrika* **56**,
222 627 (1969).
- 223 13. Prates, E. T. et al. Potential Pathogenicity Determinants Identified from Structural
224 Proteomics of SARS-CoV and SARS-CoV-2, *Mol. Biol Evol* **38**, 702 (2021).
- 225 14. Flower, T. G. et al. Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion
226 protein, *Proc. Natl. Acad. Sci. U. S A* **118**, e2021785118 (2021).
- 227 15. Elena, S. F. et al. The two faces of mutation: extinction and adaptation in RNA viruses,
228 *IUBMB Life*. **49**, 5 (2000).
- 229 16. Jensen, J. D. et al. Imposed mutational meltdown as an antiviral strategy, *Evolution* **74**,
230 2549 (2020).
- 231 17. van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in
232 SARS-CoV-2, *Nat. Commun.* **11**, 5986 (2020).
- 233 18. Miralles, R. et al. Clonal interference and the evolution of RNA viruses, *Science* **285**,
234 1745 (1999).
- 235 19. Muller, H. J. The relation of recombination to mutational advance, *Mutat. Res.* **106**, 2
236 (1964).

- 237 20. Elena, S. F. & Moya, A. Rate of deleterious mutation and the distribution of its effects on
238 fitness in vesicular stomatitis virus, *J. Evol. Biol.* **12**, 1078 (1999).
- 239 21. Nemudryi, A. et al. SARS-CoV-2 genomic surveillance identifies naturally occurring
240 truncation of ORF7a that limits immune suppression, *Cell Rep.* **35**, 109197 (2021).
- 241 22. Georgiades, K. et al. Gene gain and loss events in Rickettsia and Orientia species, *Biol*
242 *Direct.* **6**, 6 (2011).
- 243 23. Pereira, F. SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin,
244 *Gene* **784**, 145596 (2021).
- 245 24. Bliven, K. A. & Maurelli, A. T. Antivirulence genes: insights into pathogen evolution
246 through gene loss, *Infect. Immun.* **80**, 4061 (2012).
- 247 25. Morris, J. J., Lenski, R. E. & Zinser, E. R. The Black Queen Hypothesis: evolution of
248 dependencies through adaptive gene loss, *MBio.* **3**, mBio-12 (2012).
- 249 26. Moran, N. A. Microbial minimalism: genome reduction in bacterial pathogens, *Cell.* **108**,
250 583 (2002).
- 251 27. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in
252 China, *Science* **303**, 1666 (2004).
- 253 28. Corman, V. M. et al. Evidence for an Ancestral Association of Human Coronavirus 229E
254 with Bats, *J. Virol.* **89**, 11858 (2015).
- 255 29. Valcarcel, A. et al. Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and
256 Therapeutic Implications, *Front. Genet.* **12**, 693227 (2021).
- 257 30. Kerr, P. J. et al. Evolutionary history and attenuation of myxoma virus on two continents,
258 *PLoS. Pathog.* **8**, e1002950 (2012).
- 259 31. Hodcroft, E. CoVariants: SARS-CoV-2 mutations and variants of interest. (2012).
260 Available from: <https://covariants.org/>.

261

262 **TABLES**

263

264 **Table 1.** Characteristics of 1,828 patients infected with Marseille-4A or Marseille-4B (a) and
 265 risk factor analysis for hospitalization, transfer to the intensive care unit and death in 1647
 266 patients infected with Marseille-4A or Marseille-4B (b).

267

268 **a.** Characteristics of 1,828 patients infected with Marseille-4A or Marseille-4B.

Epidemiological, clinical and virological features	Marseille-4A	Marseille-4B	p value
Male sex (%)	790 (48.0)	74 (40.9%)	0.0710
Mean age in years (standard deviation)	51.3 (24.1)	57.5 (21.5)	0.0008
Mean qPCR Ct Value (standard deviation)	20.0 (3.5)	20.1 (3.8)	0.9246
Hospitalization (%)	195 (11.8)	34 (18.8)	0.0124
Transfer to intensive care unit (%)	59 (3.6)	7 (3.9)	0.8330
Death (%)	72 (4.4)	17 (9.4)	0.0058

269

270 **b.** Risk factor analysis for hospitalization, transfer to the intensive care unit and death in 1,647
 271 patients infected with Marseille-4A or Marseille-4B.

Epidemiological, clinical and virological features	OR (95% CI, p value)		
	Hospitalization	Transfer to intensive care unit	Death
Male sex	1.48 (1.08-2.03, p=0.0142)	4.70 (2.21-10, p<.0001)	3.07 (1.85-5.1, p<.0001)
Age	1.06 (1.05-1.06, p<.0001)	1.03 (1.02-1.05, p<.0001)	1.07 (1.06-1.09, p<.0001)
qPCR Ct value	1.09 (1.05-1.14, p<.0001)	1.07 (0.98-1.16, p=0.1368)	0.97 (0.91-1.04, p=0.3478)
Presence of the stop codon 64 in ORF8	2.24 (1.41-3.56, p=0.0006)	1.18 (0.41-3.43, p=0.7625)	2.60 (1.36-4.98, p=0.0039)

272

273 **FIGURE LEGENDS**

274

275 **Figure 1.** Weekly incidence of SARS-CoV-2 diagnoses at the IHU Méditerranée Infection,
276 Marseille, France and incidence of the SARS-CoV-2 Marseille-4 variant (a) and spread of the
277 Marseille-4 variant in France and three additional European countries (b).

278 Figure 1b is adapted from screenshots from the CoVariants website (<https://covariants.org/>)³¹.

279

280 **Figure 2.** Phylogenetic tree of SARS-CoV-2 Marseille-4 genome sequences obtained from
281 patients diagnosed with SARS-CoV-2 infection at IHU Méditerranée Infection (a) and growth
282 rate of the Marseille-4 variant overall (b) and of four Marseille-4A lineages (c-f) and of the
283 Marseille-4B lineage (g).

284 b-g: Time series of the number of mutations from the variant root of each subvariant or
285 lineage along with the loess (locally estimated scatterplot smoothing) regression curve and its
286 95% confidence interval.

287

288 **Figure 3.** Structure of the SARS-CoV-2 ORF8 protein and its mutated and truncated forms
289 (a-c), and signature mutations in the genomes obtained for each of the Marseille-4 subvariants
290 and lineages (d).

291 a-c: The upper panel (a) shows the structure of dimeric SARS-CoV-2 ORF8 shown as
292 superimposed surface and cartoon representations. The missing amino acids (65-66 in chain A
293 and 66-68 in chain B) were inserted with Swiss-PdbViewer in PDB: 7JTL, and the resulting
294 model was minimized using the Polak-Ribiere algorithm of Hyperchem. Residue A65 in both
295 chains is highlighted in cyan. The structure of the ORF8 mutant A65S (highlighted in green)
296 was modelled using Swiss-PdbViewer and Hyperchem (middle panels) (b). The structure of
297 truncated ORF8 18-63 (bottom panels) was obtained using Hyperchem (c). For all models, the

298 surface potential of the protein is shown in the right panels (blue, positive; red, negative;

299 white, neutral).

300 b: Synonymous nucleotide changes are indicated by a grey background. Non-synonymous


301 nucleotide changes are indicated by a black background.

302

303

Figure 1.

a.



b.











Figure 2.**a.****b.****c.****d.****e.****f.****g.**

1 **Methods**

2

3 **Patients**

4 Patients included in the present study were those identified as infected with the SARS-CoV-2
5 Marseille-4 variant^{1,2}. The present study has been approved by the ethics committee of
6 University Hospital Institute (IHU) Méditerranée Infection (N°2020-016-3). Epidemiological
7 and clinical data were retrieved for patients registered in the Assistance Publique-Hôpitaux de
8 Marseille (APHM) information system. Access to the patients' biological and registry data
9 issued from this system was approved by the data protection committee of APMH and was
10 recorded in the European General Data Protection Regulation registry under number
11 RGPD/APHM 2019-73. Statistical processes were performed using R software version 4.0.2
12 (<https://cran.r-project.org/>). A $p < 0.05$ was considered statistically significant.

13

14 **SARS-CoV-2 genotyping**

15 SARS-CoV-2 genotyping was performed from nasopharyngeal samples tested between 1 July
16 2020 and 30 April 2021 (10 months) at the IHU Méditerranée Infection Institute
17 (<https://www.mediterranee-infection.com/>). Next-generation sequencing was performed when
18 the cycle threshold value (Ct) of the qPCR used to diagnose SARS-CoV-2 infection was < 30 .
19 When the Ct was ≥ 30 and in any case in the absence of an available genome sequence, the
20 genotype was determined for SARS-CoV-2-positive specimens using variant-specific qPCR,
21 as previously described^{1,2,3}. Viral RNA was extracted from 200 μ L of nasopharyngeal swab
22 fluid using the EZ1 Virus Mini Kit v2.0 and the EZ1 Advanced XL instrument (Qiagen,
23 Courtaboeuf, France) or the KingFisher Flex system (Thermo Fisher Scientific, Waltham,
24 MA, USA) following the manufacturer's instructions. SARS-CoV-2 genome sequences were
25 obtained as follows: by next-generation sequencing using Illumina technology, the Nextera

26 XT paired end strategy and the MiSeq instrument (Illumina Inc., San Diego, CA, USA) since
27 February 2020, as previously described²; using the Illumina COVID-seq protocol and the
28 NovaSeq 6000 instrument (Illumina Inc.) since April 2021; or using Oxford Nanopore
29 technology (ONT) and the GridION instrument (Oxford Nanopore Technologies Ltd., Oxford,
30 UK), as previously described². Next-generation sequencing with ONT was performed without
31 or with (since March 2021) synthesized cDNA amplification using a multiplex PCR protocol
32 with ARTIC nCoV-2019 v3 Panel primers purchased from Integrated DNA technologies
33 (IDT, Coralville, IA, USA) according to the ARTIC procedure (<https://artic.network/>), as
34 previously described. Postextraction, viral RNA was reverse-transcribed using SuperScript IV
35 (Thermo Fisher Scientific) before cDNA second strand synthesis with Klenow Fragment
36 DNA polymerase (New England Biolabs, Beverly, MA, USA) when performing NGS using
37 the Illumina MiSeq instrument (Illumina Inc.)², LunaScript RT SuperMix kit (New England
38 Biolabs) when performing NGS with the ONT, or according to the COVIDSeq protocol
39 (Illumina Inc.) following the manufacturer's recommendations. The generated cDNA was
40 purified using Agencourt AMPure XP beads (Beckman Coulter, Villepinte, France) and
41 quantified using a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA).

42

43 **Assembly and analyses of genome sequences**

44 Genome sequences were assembled by mapping on the SARS-CoV-2 genome GenBank
45 accession no. NC_045512.2 (Wuhan-Hu-1 isolate) using CLC Genomics workbench v.7 (with
46 the following thresholds: 0.8 for coverage and 0.9 for similarity)
47 (<https://digitalinsights.qiagen.com/>) as previously described² or Minimap2
48 (<https://github.com/lh3/minimap2>)⁴. Samtools (<https://www.htslib.org/>) was used for soft
49 clipping of Artic primers (<https://artic.network/>) and to remove sequence duplicates⁵.
50 Consensus genomes were generated using CLC Genomics workbench v.7 and Sam2consensus

51 (<https://github.com/vbsreenu/Sam2Consensus>) through a first in-house script written in
52 Python language (<https://www.python.org/>). Mutation detection was performed using the
53 Nextclade tool (<https://clades.nextstrain.org/>) and freebayes
54 (<https://github.com/freebayes/freebayes>)⁶ using a mapping quality score of 20 and results
55 filtered by the Python script based on major nucleotide frequencies $\geq 70\%$ and nucleotide
56 depths ≥ 10 (when sequence reads were generated on the NovaSeq Illumina instrument
57 (Illumina Inc.)) or ≥ 5 (when sequence reads were generated on the MiSeq Illumina
58 instrument). SARS-CoV-2 genotyping was performed using a second in-house script written
59 in Python language (<https://www.python.org/>) by comparing mutation patterns with those of
60 our database of SARS-CoV-2 variants. Nextstrain clades and Pangolin lineages provided in
61 the present study were determined using the Nextclade web application
62 (<https://clades.nextstrain.org/>)^{7,8} and Pangolin web application ([https://cov-
64 lineages.org/pangolin.html](https://cov-
63 lineages.org/pangolin.html))⁹, respectively. The sequences described in the present study have
64 been deposited in the GISAID sequence database (<https://www.gisaid.org/>)¹⁰ and can be
65 retrieved online using the GISAID online search tool with “Marseille” as a keyword, and then
66 selecting sequence names containing “IHU” or “MEPHI”. The sequences have also been
67 deposited in the IHU Marseille Infection website: [https://www.mediterranee-
69 infection.com/tout-sur-le-coronavirus/sequencage-genomique-sars-cov-2/](https://www.mediterranee-
68 infection.com/tout-sur-le-coronavirus/sequencage-genomique-sars-cov-2/).

70 **Phylogenetic reconstruction and definition and naming of Marseille-4 subvariants and** 71 **lineages**

72 Phylogenetic reconstruction based on SARS-CoV-2 genomes were performed for genome
73 sequences $>24,000$ nucleotides using the 3extstrain/ncov tool
74 (<https://github.com/nextstrain/ncov>) and then were visualized using Auspice
75 (<https://docs.nextstrain.org/projects/auspice/en/stable/>).

76

77 **Structural analysis of the untruncated and truncated ORF8 protein**

78 A structural model of the ORF8 protein was generated from pdb file 7JTL¹¹. The gaps in the
79 crystal structure were fixed by incorporating the missing amino acids with the Robetta protein
80 structure prediction tool¹², followed by energy minimization with the Polak-Ribière algorithm
81 as previously reported¹³. Mutant and truncated proteins were then generated with Swiss-
82 PdbViewer¹⁴ and submitted to several rounds of energy minimization as described¹⁵.

83

84 **Evolution of Marseille-4 subvariants and lineages and time dynamics of SARS-CoV-2** 85 **mutation accumulation**

86 Duration of circulation of the different subvariants and lineages was calculated using the
87 differences between the 5th and 95th percentiles of sampling dates; this allowed considering
88 the time periods during which the subvariants and lineages had a significant incidence.
89 Time dynamics of mutation accumulation were analysed using locally estimated scatterplot
90 smoothing (loess) for regression fitting. Latent structural changes in mutation distributions
91 were retrieved using change point analysis of mean and variance with binary segmentation
92 method and Schwartz information criterion penalty associated with a penalty threshold of
93 0.05¹⁶. We assessed the epidemiological capabilities of subvariants using the early stages of
94 each epidemic curve. During this exponential phase, the size of the susceptible population
95 may be considered as constant, and the cumulated number of cases exponentially increases at
96 an approximately constant rate that was defined as the growth rate. After logarithmic
97 transformation, the cumulated number of cases followed a linear model as follows: $\ln(I_t) =$
98 $\ln(I_0) + \Lambda t$, where I_t is the cumulated incidence at time t , I_0 is the initial number of cases, and
99 Λ is the regression slope and the growth rate. From Λ , the reproduction rate, R , may be easily
100 retrieved using the following equation¹⁷: $R = (I + \Lambda D)(1 + \Lambda D')$, where D and D' are the

101 average infectious and pre-infectious periods (according to the SEIR model). Here, we set D
102 at 9.3^{18} and d' at 3.3^{19} . To calculate the growth rate, we used Chow's F test to determine the
103 inflexion point of the logarithm of cumulated number of cases, which corresponded to the end
104 of the exponential phase. Then, we applied a linear model for this phase to obtain the
105 regression slope (i.e. the growth rate) and its 95% confidence interval. Statistical processes
106 were performed using R software version 4.0.2 (<https://cran.r-project.org/>). All statistical
107 conclusions were made using a 0.05 threshold.

108

109

110 **References**

111

- 112 1. Fournier, P. E. et al. Emergence and outcomes of the SARS-CoV-2 'Marseille-4' variant,
113 *Int. J. Infect. Dis.* **106**, 228 (2021).
- 114 2. Colson, P. et al. Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the
115 role of globalisation and zoonosis in pandemics, *Front. Microbiol.*, Online ahead of print
116 (2022).
- 117 3. Bedotto, M. et al. Implementation of an in-house real-time reverse transcription-PCR
118 assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant, *J Clin. Virol* **139**,
119 104814 (2021).
- 120 4. Li, H. Minimap2: pairwise alignment for nucleotide sequences, *Bioinformatics.* **34**, 3094
121 (2018).
- 122 5. Li, H. et al. The Sequence Alignment/Map format and SAMtools, *Bioinformatics.* **25**,
123 2078 (2009).
- 124 6. Garrison, E.& Marth, G. Haplotype-based variant detection from short-read sequencing.
125 *arXiv. org* (2012).

- 126 7. Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution, *Bioinformatics*.
127 **34**, 4121 (2018).
- 128 8. Aksamentov, I., Roemer, C., Hodcroft, E. B.& Neher, R. A. Nextclade: clade assignment,
129 mutation calling and quality control for viral genomes. *J Open Source Softw* **6**, 3773
130 (2021).
- 131 9. Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
132 genomic epidemiology, *Nat. Microbiol.* **5**, 1403-1407 (2020).
- 133 10. Elbe, S., & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
134 contribution to global health. *Glob Chall* **1**, 33-46 (2017).
- 135 11. Flower, T. G. et al. Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion
136 protein, *Proc. Natl. Acad. Sci. U. S A* **118** (2021).
- 137 12. Kim, D. E., Chivian, D.& Baker, D. Protein structure prediction and analysis using the
138 Robetta server, *Nucleic Acids Res* **32**, W526-W531 (2004).
- 139 13. Fantini, J. et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring
140 strategy for anticipating Covid-19 outbreaks, *J. Infect.* **83**, 197-206 (2021).
- 141 14. Guex, N.& Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment
142 for comparative protein modeling, *Electrophoresis* **18**, 2714 (1997).
- 143 15. Di Scala. C.& Fantini, J. Hybrid In Silico/In Vitro Approaches for the Identification of
144 Functional Cholesterol-Binding Domains in Membrane Proteins, *Methods Mol. Biol*
145 **1583**, 7 (2017).
- 146 16. Chen, J. & Gupta, A. K. *Parametric statistical change point analysis with applications to*
147 *genetics, medicine, and finance*, 2nd ed. (Birkhauser, 2012).
- 148 17. White, R. & Vynnycky, E. *An introduction to infectious disease modelling*, Oup Oxford
149 ed. (2016).

- 150 18. Zhao, S. et al. Estimating the generation interval and inferring the latent period of
151 COVID-19 from the contact tracing data, *Epidemics*. **36**, 100482 (2021).
- 152 19. Byrne, A. W. et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping
153 review and analysis of available evidence for asymptomatic and symptomatic COVID-19
154 cases, *BMJ Open*. **10**, e039856 (2020).

155

156

157 **Acknowledgments**

158 This work was supported by the French Government under the “Investments for the Future”
159 program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-
160 IAHU-03 and the Emergen Consortium
161 (<https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen>). We
162 also acknowledge support from the Région Provence Alpes Côte d’Azur and European
163 funding FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de
164 Recherche et d’Innovation Mutualisées Méditerranée Infection), FEDER PA 0000320
165 PRIMMI.

166 We are thankful to Mamadou Beye, Emilie Burel, Elsa Prudent, Céline Gazin, Sofiane
167 Bakour, Laurence Thomas, Séverine Guillon, Véronique Filosa, Ludivine Bréchar, and
168 Claudia Andrieu for their technical help.

169

170 **Author contributions**

171 Study conception and design: D.R., P.C., B.L.S., P.E.F, P.G.. Materials, data and analysis
172 tools: P.C., P.G., J.D., H.C., M.B., L.D., A.L., J.C.L., M.M., N.Y., J.F., P.E.F.. Data analyses:
173 D.R., P.C., H.C., J.D., M.B., L.D., N.Y., J.F., B.L.S., P.E.F.. Writing of the first draft of the
174 manuscript: P.C. and D.R.. Critical reviews of and revisions to the manuscript: D.R., P.C.,

175 P.G., P.P., P.F., J.F., B.L.S., P.E.F.. All authors approved the final manuscript. Supervision:
176 D.R..

177

178 **Competing interests**

179 D.R. is a scientific board member of Eurofins company, a founder of a microbial culture
180 company (Culture Top), and was a consultant for Hitachi High-Technologies Corporation,
181 Tokyo, Japan from 2018 to 2020. All other authors do not have any competing interest to
182 declare. Funding sources had no role in the design and conduct of the study; collection,
183 management, analysis, and interpretation of the data; and preparation, review, or approval of
184 the manuscript.

185

186 **Funding**

187 French Government under the “Investments for the Future” program managed by the National
188 Agency for Research (ANR), no. Méditerranée-Infection 10-IAHU-03, and the “Emergen
189 Consortium” ([https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-](https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen)
190 [emergen](https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen)).; Région Provence Alpes Côte d’Azur and European funding FEDER PRIMMI
191 (Fonds Européen de Développement Régional-Plateformes de Recherche et d’Innovation
192 Mutualisées Méditerranée Infection), no. FEDER PA 0000320 PRIMMI.

193

194 **Data availability**

195 The dataset generated and analyzed during the current study are available in the GISAID
196 database (<https://www.gisaid.org/>).

197

198 **Extended data figure/table legends**

199 See Supplementary Material.

200 **Supplementary material**

201

202 **Supplementary figure legends**

203

204 **Supplementary Figure S1a-f.** Time series for the different Marseille-4 subvariants and
205 lineages of the number of mutations showing both the loess regression curve and the overall
206 Marseille-4 loess regression curve, with their 95% confidence intervals.
207 MRS, Marseille.

208

209 **Supplementary Figure S2.** Forest plot like representation of the growth rates of subvariants
210 and lineages with their 95% confidence intervals.

211

212 **Supplementary Figure S3.** Temporal distribution of the genome sequences of SARS-CoV-2
213 Marseille-4 subvariants and lineages obtained from patients diagnosed with SARS-CoV-2
214 infection at IHU Méditerranée Infection.

215

216

217 **Supplementary Tables**

218

219 **Supplementary Table S1.** List of nucleotide and amino acid changes associated with the onset and expansion of Marseille-4A and Marseille-4B

220 subvariants and lineages.

Marseille-4 subvariants and lineages	Nucleotide changes (hallmark mutations)	Amino acid changes (hallmark mutations)
Marseille-4A.01	C23191U	-
Marseille-4A.02	G28086U	ORF8: A65S
Marseille-4A.03	G487A	-
Marseille-4A.04	C222U	-
Marseille-4A.05	C3096U; C23188U	ORF1a: S944L; -
Marseille-4A.06	G29701A	-
Marseille-4A.07	C27434U	ORF7a: T14I
Marseille-4A.08	G571A	-
Marseille-4A.09	G2600U	ORF1a: V779F
Marseille-4A.10	G27877U	ORF7b: C41F
Marseille-4A.11	U26442C; G29511U	-; N: S413I
Marseille-4A.12	C503U; G28178U	ORF1a: P80S; ORF8: L95F
Marseille-4A.13	C1551U; A11822G; C13548U; C22388U; G27816A	ORF1a: A429V; ORF1a: I3853V; -; -; ORF7b: V21I
Marseille-4A.14	G7925U	ORF1a: A2554S
Marseille-4A.15	C9866A; C26060U	ORF1a: L3201I; ORF3a: T223I
Marseille-4A.16	G25340A; C29445U	S: D1260N; N: T391I
Marseille-4A.17	G28655U	N: D128Y
Marseille-4A.18	G26062U	ORF3a: G224C
Marseille-4A.19	C6555U	ORF1a: A2097V
Marseille-4A.20	A4870G	-
Marseille-4A.21	C3743U	-
Marseille-4A.22	U5071C; G8102U	-; ORF1a: V2613F
Marseille-4B	G204U; C5622U; C9924U; G17488A; G28083U; G29778U	-; -; ORF1a: A3220V; ORF1b: E1341K; ORF8: E64*; -

221 See also Figure 3d; -, no amino acid change; *, Stop codon

222

223 **Supplementary Table S2.** Time dynamics of Marseille-4 subvariants and lineages.

224

Subvariants and lineages	Number of genomes	Change point (weeks)	Growth rate	Lower limit of growth rate (95% confidence interval)	Upper limit of growth rate (95% confidence interval)	p-value *
Marseille-4A.01	121	32	0.133	0.118	0.149	3.08E-17
Marseille-4A.02	685	35	0.097	0.087	0.107	8.61E-20
Marseille-4A.03	404	48	0.059	0.049	0.069	4.97E-15
Marseille-4A.04	339	34	0.157	0.147	0.168	7.47E-25
Marseille-4A.05	207	76	0.027	0.024	0.031	1.14E-24
Marseille-4A.06	374	32	0.118	0.104	0.131	1.56E-17
Marseille-4A.07	157	52	0.046	0.038	0.053	4.81E-17
Marseille-4A.08	112	33	0.102	0.087	0.117	1.78E-14
Marseille-4A.09	84	33	0.118	0.097	0.140	1.66E-12
Marseille-4A.10	171	35	0.110	0.103	0.117	3.63E-27
Marseille-4A.11	78	30	0.103	0.093	0.112	1.85E-19
Marseille-4A.12	131	27	0.080	0.071	0.089	4.24E-16
Marseille-4A.13	76	25	0.104	0.094	0.114	2.06E-16
Marseille-4A.14	96	42	0.057	0.048	0.065	1.08E-16
Marseille-4A.15	91	19	0.173	0.147	0.199	8.18E-11
Marseille-4A.16	99	106	0.020	0.018	0.022	5.42E-35
Marseille-4A.17	114	66	0.010	0.006	0.014	1.27E-06
Marseille-4A.18	60	57	0.040	0.034	0.046	6.89E-20
Marseille-4A.19	74	68	0.030	0.028	0.033	3.45E-38
Marseille-4A.20	52	24	0.086	0.072	0.101	1.81E-11
Marseille-4A.21	52	27	0.078	0.060	0.097	6.15E-09
Marseille-4A.22	87	119	0.023	0.021	0.024	1.30E-62
Marseille-4B	1,319	94	0.052	0.049	0.055	5.02E-52

225

226 * P-values are for the statistical significance of the growth rate

227

228 **Supplementary Table S3.** Number of genomes, number of mutations and time duration for Marseille-4 subvariants and lineages.


229

Subvariants and lineages	Number of genomes	Total number of mutations				Number of additional mutations relatively to the root				Raw data			5 th and 95 th percentiles		
		Mean	Standard deviation	Minimum	Maximum	Mean	Standard deviation	Minimum	Maximum	Minimum date	Maximum date	Duration (months)	Minimum date	Maximum date	Duration (months)
Marseille-4A	2 470	21,9	3,0	14	35	3,0	2,6	0	13	29/07/2020	26/03/2021	7,9	14/08/2020	04/02/2021	5,7
Marseille-4A.01	121	22,9	2,7	17	29	3,2	2,1	0	10	25/08/2020	08/02/2021	5,5	07/09/2020	25/01/2021	4,6
Marseille-4A.02	685	24,6	3,3	15	33	4,5	2,8	0	12	12/08/2020	23/03/2021	7,3	27/08/2020	08/02/2021	5,4
Marseille-4A.03	404	24,3	3,0	16	32	4,1	2,5	0	11	09/09/2020	08/03/2021	5,9	01/10/2020	11/02/2021	4,4
Marseille-4A.04	339	24,7	2,9	19	36	4,0	2,7	0	15	11/08/2020	12/03/2021	7,0	02/09/2020	14/01/2021	4,4
Marseille-4A.05	207	24,6	2,2	17	31	3,1	1,9	0	9	11/08/2020	10/03/2021	6,9	28/08/2020	04/02/2021	5,2
Marseille-4A.06	374	23,9	3,2	14	31	3,7	2,7	0	10	26/08/2020	22/03/2021	6,8	08/09/2020	09/02/2021	5,1
Marseille-4A.07	157	24,7	3,5	15	32	4,6	2,8	0	11	28/08/2020	17/03/2021	6,6	04/09/2020	12/02/2021	5,3
Marseille-4A.08	112	23,0	2,5	17	30	2,7	2,2	0	10	20/08/2020	23/01/2021	5,1	26/08/2020	10/01/2021	4,5
Marseille-4A.09	84	22,7	1,6	18	27	1,9	1,2	0	6	22/08/2020	29/12/2020	4,2	26/08/2020	10/10/2020	1,5
Marseille-4A.10	171	27,3	4,2	18	35	7,3	3,7	0	14	10/08/2020	24/03/2021	7,4	03/09/2020	18/02/2021	5,5
Marseille-4A.11	78	23,0	3,4	16	31	2,5	2,3	0	9	10/09/2020	09/02/2021	5,0	16/09/2020	27/01/2021	4,3
Marseille-4A.12	131	24,7	2,6	19	34	3,2	2,4	0	12	07/10/2020	30/03/2021	5,7	16/09/2020	27/01/2021	4,3
Marseille-4A.13	76	27,3	3,5	20	35	4,3	2,5	1	10	15/10/2020	02/02/2021	3,6	21/10/2020	19/01/2021	2,9
Marseille-4A.14	96	23,4	2,7	15	29	3,5	2,0	0	8	13/09/2020	19/02/2021	5,2	28/09/2020	12/02/2021	4,5
Marseille-4A.15	91	31,5	1,7	24	35	9,7	1,2	6	13	13/01/2021	01/04/2021	2,6	22/01/2021	24/02/2021	1,1
Marseille-4A.16	99	25,2	2,2	18	29	3,6	1,7	0	7	13/10/2020	24/03/2021	5,3	28/10/2020	17/03/2021	4,6
Marseille-4A.17	114	24,0	2,0	16	28	3,5	1,4	0	7	23/08/2020	23/03/2021	7,0	28/10/2020	08/03/2021	4,3
Marseille-4A.18	60	25,0	3,9	18	33	4,8	3,5	1	12	03/09/2020	26/03/2021	6,7	16/09/2020	22/02/2021	5,2
Marseille-4A.19	74	24,7	3,1	16	29	4,5	2,1	0	8	26/08/2020	09/02/2021	5,5	17/09/2020	01/02/2021	4,5
Marseille-4A.20	52	23,4	4,1	16	31	3,4	3,1	0	10	17/10/2020	28/02/2021	4,4	17/10/2020	19/02/2021	4,1
Marseille-4A.21	52	21,8	1,3	16	26	1,2	1,0	0	7	01/10/2020	06/02/2021	4,2	17/10/2020	12/11/2020	0,8
Marseille-4A.22	87	27,7	2,5	17	33	6,2	1,9	1	11	03/09/2020	26/03/2021	6,7	15/10/2020	06/03/2021	4,7
Marseille-4B	1 319	27,4	2,1	18	36	4,1	1,6	0	15	29/07/2020	19/04/2021	8,7	22/12/2020	10/03/2021	2,6
Total	7 453	24,3	3,6	14	36	3,8	2,6	0	15	29/07/2020	19/04/2021	8,7	26/08/2020	23/02/2021	6,0


230

Supplementary Figure S1a.


MRS-4A (loess)




MRS-4A.01 (loess)



MRS-4A.02 (loess)




MRS-4A.03 (loess)




Supplementary Figure S1b.


MRS-4A.04 (loess)




MRS-4A.05 (loess)







MRS-4A.06 (loess)







MRS-4A.07 (loess)







Supplementary Figure S1c.







Supplementary Figure S1d.




Supplementary Figure S1e.



Supplementary Figure S1f.



Supplementary Figure S2.



Supplementary Figure S3.

